NEO GENOMICS

Profiling Hematologic Malignancies with Next-Generation Sequencing

NeoTYPE® Hematologic Disease Profiles

NeoGenomics offers comprehensive next-generation sequencing (NGS) testing for hematologic malignancies to analyze known driver mutations for both myeloid and lymphoid disease and provide the most thorough molecular assessment available for diagnosis, prognosis, and monitoring.

- Integrated reporting with summary of results that includes diagnostic, prognostic, therapeutic, and clinical trials information
- Plasma Profile testing option for when bone marrow biopsy is not available or inadequate
- Flexible level of service with FISH components orderable as Tech-Only or Global

NeoTYPE Heme Cancer-Specific Profile Highlights

- **Targeted** — Test design is tailored to driver mutations in specific cancers
- **Actionable** — All genes have clinical significance when mutated
- **Comprehensive** — Unique reporting of diagnostic, prognostic, and therapeutic implications
- **Efficient** — Fast TAT's allow NeoTYPE to replace first-line single-gene testing
- **Cost-effective** — When compared to single-gene testing

NeoTYPE Heme Broad Pan-Cancer Profile Highlights

- **Expansive** — Designed to detect a wide spectrum of genomic alterations in a variety of cancers concurrently
- **Dynamic** — Helpful for screening patients with an unusual clinical presentation
- **Pharma-ready** — Useful for academic or clinical research

Specimen Requirements

- **Bone marrow (Preferred):** 2 mL in EDTA tube
- **Peripheral blood:** 5 mL in EDTA tube
- **FFPE tissue:** Paraffin block. Alternatively, 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Positively-charged slides are preferred and 10% NBF fixative is the recommended fixative. No zinc or mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.

Specimen requirements vary by test. Please check **neogenomics.com** for specific tests' requirements.

Turnaround Time

- 14 Days

Gene lists on next page >

NeoTYPE® tests are available in multiplex profiles.

Multiplex NeoTYPE Profiles	
AITL/Peripheral T-Cell Lymphoma Profile	**6 Genes:** BCL1 (CCND1), DNMT3A, IDH1, IDH2, RHOA, and TET2
AML Prognostic Profile	**28 Genes:** ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 (V617F and Exons 12-14), KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PML, PTPN11, RUNX1, SETBP1, STAG2, TET2, TP53, and WT1
CLL Prognostic Profile	**NGS (12 Genes):** ATM, BCL2, BIRC3, BTK, CARD11, CD79B, CXCR4, MYD88, NOTCH1, PLCG2, SF3B1, and TP53 **Other Molecular (1 Gene):** IgVH **FISH (6 Biomarkers):** 6q- [SEC63 (6q21), MYB (6q23)] | ATM (11q22.3) | p53 (17p13.1) | Trisomy 12 (Cen 12) | 13q-/-13 (13q14, 13q34) | CCND1/IgH t(11;14)
Follicular Lymphoma Profile	**NGS (15 Genes):** ARID1A, BCL2, BCL6, CDKN2A, CREBBP, EP300, EZH2, FAS, KMT2D, MAP2K1, MEF2B, PIK3CA, SOCS1, TNFAIP3, and TNFRSF14 **Fragment Analysis (1 Gene):** BCL2 **FISH (2 Biomarkers):** TNFRSF14 (1p36) | DUSP22-IRF4
JMML Profile	**15 Genes:** BRAF, CBL, CEBPA, FLT3, HRAS, JAK2 (V617F and Exons 12-14), JAK3, KIT, KRAS, NPM1, NRAS, PDGFRA, PTEN, PTPN11, and SETBP1
Lymphoma Profile	**NGS (10 genes):** BCL6, BRAF, CARD11, CD79B, EZH2, MYD88, NOTCH1, NOTCH2, NRAS and TP53 **Fragment Analysis (1 Gene):** BCL2 t(14;18) **FISH (1 Biomarker):** CCND1 (BCL1)/IgH t(11;14)
MDS/CMML Profile	**40 Genes:** ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CUX1, DDX41, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2 (V617F and Exons 12-14), KIT, KRAS, MPL, NF1, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTEN, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, STAT3, TET2, TP53, U2AF1, WT1, and ZRSR2
Myeloid Disorders	**63 Genes:** ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DDX41, DNMT3A, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, GNB1, HRAS, IDH1, IDH2, IKZF1, JAK2 (V617F and Exons 12-14), JAK3, KDM6A, KIT, KRAS, MLL, MPL, MYD88, NF1, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PML , PPM1D, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, TET2, TP53, U2AF1, WT1, and ZRSR2

Contact your NeoGenomics Territory Business Manager for more information.

NEO GENOMICS
12701 Commonwealth Dr., Suite 9
Fort Myers, FL 33913
Phone: 866.776.5907 | Fax: 239.690.4237
neogenomics.com